Sotorasib: First Approval
Open accessThe DOI matches its Crossref record; 11 of the 11 references it cites were found in a registry or an index.
Abstract
) is a RAS GTPase family inhibitor being developed by Amgen for the treatment of solid tumours with KRAS mutations, including non-small cell lung cancer (NSCLC) and colorectal cancer. In May 2021, sotorasib was granted accelerated approval by the US FDA for the treatment of adult patients with KRAS G12C-mutated locally advanced or metastatic NSCLC, as determined by an FDA-approved test, who have received at least one prior systemic therapy. This article summarizes the milestones in the development of sotorasib leading to this first approval for KRAS G12C-mutated NSCLC.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“Surprisingly, in 2021, after unremitting efforts, a milestone was achieved: the KRASG12C inhibitor sotorasib was approved by the FDA for a specific subgroup of patients with non-small cell lung cancer (NSCLC),10”
From Recent advances in targeting the “undruggable” proteins: from drug discovery to clinical trials (2023) · cites this paper as [10]
In the citing paper
“In recent years, two KRAS G12C inhibitors, sotorasib and adagrasib, have been approved by the United States Food and Drug Administration (US FDA) for the treatment of patients with locally advanced or metastatic non-small-cell lung cancer (NSCLC), 8,9 but not in mCRC as monotherapy as to date.”
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The Clinical KRAS(G12C) Inhibitor AMG 510 Drives Anti-Tumour Immunity
Canon, J., Rex, K., Saiki, A. Y., Mohr, C., Cooke, K., Bagal, D., Gaida, K., Holt, T., Knutson, C. G., Koppada, N., et al. (2019) · Nature · doi:10.1038/s41586-019-1694-1 · Cited by 2,277
KRAS G12C Inhibition with Sotorasib in Advanced Solid Tumors
Hong, D. S., Fakih, M. G., Strickler, J. H., Desai, J., Durm, G. A., Shapiro, G. I., Falchook, G. S., Price, T. J., Sacher, A., Denlinger, C. S., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa1917239 · Cited by 1,733
Targeting KRAS(G12C): From Inhibitory Mechanism to Modulation of Antitumor Effects in Patients
Kim, D., Xue, J. Y., & Lito, P. (2020) · Cell · doi:10.1016/j.cell.2020.09.044 · Cited by 239
New Treatment Strategies for Metastatic Pancreatic Ductal Adenocarcinoma
Singh, R. R., & O’Reilly, E. M. (2020) · Drugs · doi:10.1007/s40265-020-01304-0 · Cited by 156
Li, B., Skoulidis, F., Falchook, G., Sacher, A., Velcheti, V., Dy, G., Price, T., Borghaei, H., Schuler, M., Kato, T., et al. (2021) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2021.01.321 · Cited by 30
Skoulidis, F., Li, B. T., Govindan, R., Dy, G. K., Shapiro, G., Bauml, J., Schuler, M. H., Addeo, A., Kato, T., Besse, B., et al. (2021) · Journal of Clinical Oncology · doi:10.1200/jco.2021.39.15_suppl.9003 · Cited by 24 · cited 1×
“The clinical benefit of sotorasib was also seen regardless of age (< 65 vs ≥ 65 years), ECOG PS (0 vs 1), metastatic disease (yes vs no), prior lines of therapy (1 vs ≥ 2), prior anti-PD-1/PD-L1 therapy (yes vs no), TP53 co-mutation (wild-type vs mutant), STK11 comutation (wild-type vs mutant), KEAP1 co-mutation (wild…”
BackgroundReck, M., Spira, A. I., Besse, B., Wolf, J. M., Skoulidis, F., Borghaei, H., Goto, K., Park, K., Griesinger, F., Felip, E., et al. (2020) · Annals of Oncology · doi:10.1016/j.annonc.2020.08.1730 · Cited by 21
Saiki, A. Y., Gaida, K., Rex, K., Achanta, P., Miguel, T. S., Koppada, N., Bagal, D., Lanman, B. A., Foti, R. S., McCarter, J. D., et al. (2019) · Cancer Research · doi:10.1158/1538-7445.am2019-4484 · Cited by 15
Spira, A. I., Wilson, F. H., Shapiro, G. I., Dooms, C., Fontecedro, A. C., Esaki, T., Barlési, F., Cocks, K., Trigg, A., Stevinson, K. L., et al. (2021) · Journal of Clinical Oncology · doi:10.1200/jco.2021.39.15_suppl.9057 · Cited by 13
Hong, D. S., Strickler, J. H., Fakih, M., Falchook, G. S., Li, B. T., Durm, G. A., Burns, T. F., Ramalingam, S. S., Goldberg, S. B., Frank, R. C., et al. (2021) · Journal of Clinical Oncology · doi:10.1200/jco.2021.39.15_suppl.tps2669 · Cited by 10
Research works printed but not linked: 9
- Amgen. Amgen announces first clinical data evaluating novel investigational KRASG12C inhibitor AMG 510 at ASCO 2019 [media release]. 3 Jun 2019. https://www.amgen.com/newsroom/press-releases/2019/06/amgen-announces-first-clinical-data-evaluating-novel-investigational-krasg12c-inhibitor-amg-510-at-asco-2019.
- Amgen. Amgen's sotorasib granted breakthrough therapy designation for advanced or metastatic non-small cell lung cancer patients with KRAS G12C mutation [media release]. 8 Dec 2020. https://www.amgen.com/newsroom/press-releases/2020/12/amgens-sotorasib-granted-breakthrough-therapy-designation-for-advanced-or-metastatic-nonsmall-cell-lung-cancer-patients-with-kras-g12c-mutation.
- Amgen. FDA grants sotorasib priority review designation for the treatment of patients with KRAS G12C-mutated locally advanced or metastatic non-small cell lung cancer [media release]. 16 Feb 2021. https://www.amgen.com/newsroom/press-releases/2021/02/fda-grants-sotorasib-priority-review-designation-for-the-treatment-of-patients-with-kras-g12c-mutated-locally-advanced-or-metastatic-non-small-cell-lung-cancer.
- Cardona P, Simiens M, Purkis J, et al. An open-label study to evaluate the effect of omeprazole on the pharmacokinetics of sotorasib (AMG 510) in healthy subjects [abstract no. PII-009]. Clin Pharmacol Ther. 2021;109(Suppl. 1):S31.
- Cardona P, Spring M, Purkis J, et al. An open-label study to evaluate the effect of single and multiple doses of rifampin on the pharmacokinetics of sotorasib (AMG 510) in healthy subjects [abstract no. PII-010]. Clin Pharmacol Ther. 2021;109(Suppl. 1):S31.
- Vuu I, Simiens M, Purkis J, et al. A phase I, open-label study to evaluate drug-drug interactions between metformin and sotorasib (AMG 510) in healthy subjects [abstract no. PIII-018]. Clin Pharmacol Ther. 2021;109(Suppl. 1):S50.
- Cardona P, Spring M, Purkis J, et al. An open-label study to evaluate the effect of sotorasib (AMG 510) on digoxin pharmacokinetics in healthy subjects [abstract no. PII-011]. Clin Pharmacol Ther. 2021;109(Suppl. 1):S31.
- Guardant Health. Guardant360® CDx receives FDA approval as first and only liquid biopsy companion diagnostic for Amgen's LUMAKRAS™ (sotorasib) KRASG12C inhibitor for use in advanced non-small cell lung cancer [media release]. 28 May 2021. https://investors.guardanthealth.com/press-releases/press-releases/2021/Guardant360-CDx-Receives-FDA-Approval-as-First-and-Only-Liquid-Biopsy-Companion-Diagnostic-for-Amgens-LUMAKRAS-sotorasib-KRASG12C-Inhibitor-for-Use-in-Advanced-Non-Small-Cell-Lung-Cancer/default.aspx.
- QIAGEN. QIAGEN launches first FDA-approved tissue companion diagnostic to identify the KRAS G12C mutation in NSCLC tumours and expand precision medicine options in lung cancer [media release]. 28 May 2021. https://corporate.qiagen.com/newsroom/press-releases/press-release-details/2021/QIAGEN-Launches-First-FDA-approved-Tissue-Companion-Diagnostic-to-Identify-the-KRAS-G12C-Mutation-in-NSCLC-Tumours-and-Expand-Precision-Medicine-Options-in-Lung-Cancer/default.aspx.
Cited by
Molecular targeted therapy for anticancer treatment
Min, H.-Y., & Lee, H.-Y. (2022) · Experimental & Molecular Medicine · doi:10.1038/s12276-022-00864-3 · Cited by 569
Recent advances in targeting the “undruggable” proteins: from drug discovery to clinical trials
Xie, X., Yu, T., Li, X., Zhang, N., Foster, L. J., Peng, C., Huang, W., & He, G. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01589-z · Cited by 396
New insights into protein–protein interaction modulators in drug discovery and therapeutic advance
Nada, H., Choi, Y., Kim, S., Jeong, K. S., Meanwell, N. A., & Lee, K. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-02036-3 · Cited by 216
Non-Small Cell Lung Cancer Targeted Therapy: Drugs and Mechanisms of Drug Resistance
Wu, J., & Lin, Z. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms232315056 · Cited by 199
“For the treatment of adult patients with locally advanced or metastatic NSCLC with KRAS (G12C) mutations who have undergone at least one prior systemic therapy as established by the FDA-approved test, sotorasib was given accelerated approval by the FDA in May 2021 [69].”
Emerging and Re-emerging Warheads for Targeted Covalent Inhibitors: An Update
Hillebrand, L., Liang, X. J., Serafim, R. A. M., & Gehringer, M. (2024) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.3c01825 · Cited by 199
Metadata
- Authors
- Blair, H. A.
- Affiliations
- Springer Nature (New Zealand) (NZ)
- Corresponding author
- Blair, Hannah A.
- Venue
- Drugs
- Published
- 2021-08-06
- Volume
- 81
- Issue
- 13
- Pages
- 1573-1579
- ISSN
- 0012-6667 (ISSN-L)
- 1179-1950
- PMC
- PMC8531079
- OpenAlex
- W3193019540
- Cited by
- 241
- References
- 11
- Citations by year
- 2026: 39 · 2025: 45 · 2024: 53 · 2023: 46 · 2022: 53 · 2021: 5
- FWCI
- 25.39
- Type
- journal article
- Language
- en
- Update notices
- correction (2021-10-23)
- Open access
- hybrid
- doi.org
- Licence
- cc-by-nc
- creativecommons.org/licenses/by-nc/4.0 (tdm)
- creativecommons.org/licenses/by-nc/4.0 (vor)
- Locations
- Drugs (publishedVersion, cc-by-nc)
- Europe PMC (PubMed Central) (publishedVersion, other-oa)
- PubMed Central (publishedVersion, cc-by-nc)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Treatments and Mutations
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Kinase Regulation and GTPase Signaling
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer Genomics and Diagnostics
- Keywords
- sotorasib, KRAS G12C mutation, non-small cell lung cancer, drug approval, accelerated approval, colorectal cancer, solid tumors, drug development milestones
- MeSH terms
- Antineoplastic Agents, Carcinoma, Non-Small-Cell Lung, Clinical Trials as Topic, Humans, Lung Neoplasms, Piperazines, Pyridines, Pyrimidines, United States, United States Food and Drug Administration, Drug Approval, ras Proteins
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Sotorasib: First Approval. https://app.cochat.ai/papers/10.1007/s40265-021-01574-2
- The paper
- Blair, H. A. (2021). Sotorasib: First Approval. Drugs. https://doi.org/10.1007/s40265-021-01574-2
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.

